85148-95-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarbonitrile, 6-formyl(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties. 2-Pyridinecarbonitrile, 6-formyl(9CI)'s versatility in chemical reactions enables the creation of a wide range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Pyridinecarbonitrile, 6-formyl(9CI) is utilized as an intermediate for the production of various agrochemicals. Its ability to form stable derivatives makes it suitable for the development of effective pesticides, herbicides, and other agricultural chemicals that can protect crops and enhance agricultural productivity.
Used in Organic Chemistry Research:
2-Pyridinecarbonitrile, 6-formyl(9CI) is used as a building block in organic chemistry for the synthesis of complex organic compounds. Its presence of both nitrile and formyl groups allows for a variety of chemical reactions, making it a valuable component in the development of novel organic molecules with potential applications in various fields.
Used in Biological Activity Studies:
2-Pyridinecarbonitrile, 6-formyl(9CI) has been studied for its potential biological activities, making it a subject of interest in the field of biochemistry and molecular biology. Researchers explore its interactions with biological systems to understand its potential applications in therapeutics, diagnostics, or as a tool for studying biological processes.

Upstream product

• 50501-38-7 6-(hydroxymethyl)pyridine-2-carbonitrile 
• 1620-75-3 2-Cyano-6-methylpyridine 
• 931-19-1 2-methylpyridine N-oxide 
• 25813-90-5 6-Cyano-2-picoline-N-oxide 
• 120613-15-2 6-vinylpyridine-2-carbonitrile 
• 39621-11-9 6-(hydroxymethyl)picolinaldehyde 
• 104508-24-9 6-(bromomethyl)pyridine-2-carbonitrile 
• 92304-51-3 N-Methoxy-2-picolinium iodide 
• 50501-37-6 (6-cyanopyridin-2-yl)methyl acetate 
• 85148-97-6 6-Dibromomethyl-2-cyanopyridine 

Downstream Products

• 108337-76-4 2,6-dimethyl-4-(6-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 50501-38-7 6-(hydroxymethyl)pyridine-2-carbonitrile 

Relevant academic research and scientific papers

Effect of substituent in pyridine-2-carbaldehydes on their heterocyclization to 1,2,4-triazines and 1,2,4-triazine 4-oxides

A series of substituted pyridine-2-carbaldehydes were brought into heterocyclization with isonitrosoacetophenone hydrazones, followed by aromatization by the action of oxidants or by dehydration in boiling acetic acid. As a result, substituted 3-(pyridin-2-yl)-1,2,4-triazines or 3-(pyridin-2-yl)-1,2,4-triazine 4-oxides were formed. 6-Formylpyridine-2-carbonitrile failed to undergo heterocyclization, 6-methylpyridine-2-carbaldehyde and methyl 6-formylpyridine-3-carboxylate can be converted to both 1,2,4-triazine and 1,2,4-triazine 4-oxide derivative, and only 1,2,4-triazine 4 oxides were obtained from 6-bromopyridine-2-carbaldehyde and 6-formyl-3-phenylpyridine-2-carbonitrile. Convenient procedures were proposed for the synthesis of some initial pyridinecarbaldehydes.

Synthesis and spectroscopy of anionic tridentate benzimidazole-pyridine carboxylate and tetrazolate chromophore ligands

We report on seven new anionic benzimidazole-pyridine carboxylate and tetrazolate tridentate N^N^O and N^N^N ligands that are modified with chromophore (phenyl, biphenyl, naphthyl) and solubilizing groups. The ligands are UV chromophores with the lowest-energy absorption maxima at 312-335 nm and with the molar absorption coefficients of (20-25) × 103 M-1 cm-1 in DMSO solution. The ligands form neutral complexes with trivalent lanthanides and sensitize the red luminescence of europium. The triplet state energies of the deprotonated ligands, which were measured from the phosphorescence spectra of their lanthanum complexes at 77 K, are in the range of (18.8-21.1) × 103 cm-1. We also describe synthesis of non-symmetric pyridines that are 2,6- and 2,4,6-substituted with hydroxymethyl, carboxaldehyde, and carbonitrile groups.

BENZISOXAZOLE COMPOUND

Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: -(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: -(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists

A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats.

4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES

A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRx or CRxRy; if X=NRx then n is 1 or 2 and if X=CRxRy then n is 1; Rx is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry is selected from H, hydroxy, amino; or Rx and Ry may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRxRy, RC1, RC2, Rx and Ry, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: (i) formula (i), where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; and (ii) formula (ii), where Q is O or S.